Intellicheck Mobilisa, Inc. (IDN) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this company would post a loss of $0.03 per share when it actually produced a loss of $0.02, delivering a surprise of +33.33%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Intellicheck Mobilisa, whic ...

Editas Medicine (EDIT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -53.66%. A quarter ago, it was expected that this genome editing company would post a loss of $0.51 per share when it actually produced a loss of $0.43, delivering a surprise of +15.69%.Over the last four quarters, the c ...

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $5.51 per share versus the Zacks Consensus Estimate of a loss of $5.79. This compares to a loss of $14.5 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.84%. A quarter ago, it was expected that this company would post a loss of $7.5 per share when it actually produced a loss of $6, delivering a surprise of +20%.Over the last four quarters, the company has surp ...

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for allegedly misleading investors regarding the results of its IMPACT Phase 2b MASH trial, which did not meet key statistical significance markers [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - The lawsuit claims that Altimmune created a false impression of reliable information regarding trial results, while concealing negative data that would impact the topline results [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and has a strong track record in recovering funds for investors [4]. - Investors wishing to serve as lead plaintiff must file their motion by October 6, 2025 [1][3]. Group 3: Trial Results - Altimmune's IMPACT Phase 2b MASH trial failed to achieve statistical significance for the primary endpoint related to fibrosis reduction, contrary to the company's previous claims [5]. - The lawsuit alleges that the company concealed higher responses in the placebo group, which negatively affected the trial's topline results [5].

Core Viewpoint - Simon Property Group, L.P. is issuing new senior notes to refinance existing debt and support general corporate purposes, indicating a strategic move to manage its capital structure effectively [1][2]. Group 1: Financial Details - The new senior notes issuance includes $700 million of 4.375% Notes due 2030 and $800 million of 5.125% Notes due 2035, with a combined weighted average term of 7.8 years and a weighted average coupon rate of 4.775% [1][7]. - The proceeds from the offering will be used to repay a portion of the $1.1 billion outstanding principal amount of 3.500% notes due September 2025 at maturity [2]. Group 2: Offering Management - BBVA Securities Inc., J.P. Morgan Securities LLC, TD Securities (USA) LLC, and Wells Fargo Securities, LLC are acting as joint book-running managers for the public offering, which is conducted under the Operating Partnership's shelf registration statement [3].

Group 1 - Lineage Cell (LCTX) reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.03 per share a year ago, representing an earnings surprise of +50.00% [1] - The company posted revenues of $2.77 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 75.00%, compared to year-ago revenues of $1.41 million [2] - Lineage Cell shares have increased approximately 101% since the beginning of the year, significantly outperforming the S&P 500's gain of 8.4% [3] Group 2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Lineage Cell was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $2.52 million, and -$0.09 on revenues of $7.94 million for the current fiscal year [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Lineage Cell belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Biofrontera Inc. (BFRI), is expected to report a quarterly loss of $0.45 per share, reflecting a year-over-year change of +59.8%, with revenues anticipated to be $8.2 million, up 4.6% from the previous year [9]

分组1 - TriSalus Life Sciences, Inc. reported a quarterly loss of $0.27 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.22, and compared to a loss of $0.21 per share a year ago, indicating an earnings surprise of -22.73% [1] - The company posted revenues of $11.21 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.52%, and this represents an increase from year-ago revenues of $7.36 million [2] - TriSalus Life Sciences, Inc. shares have declined approximately 28.7% since the beginning of the year, contrasting with the S&P 500's gain of 8.4% [3] 分组2 - The earnings outlook for TriSalus Life Sciences, Inc. is uncertain, with current consensus EPS estimates of -$0.16 on $11.38 million in revenues for the coming quarter and -$0.86 on $44.31 million in revenues for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 42% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact the stock's performance [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lockheed Martin securities between January 23, 2024, and July 21, 2025, about the upcoming lead plaintiff deadline on September 26, 2025 [1]. Group 1: Class Action Details - Investors who bought Lockheed Martin securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by September 26, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Lockheed Martin - The lawsuit alleges that Lockheed Martin made false and misleading statements and failed to disclose critical information regarding its internal controls and risk management practices [5]. - Specific claims include the lack of effective internal controls over risk-adjusted contracts, inaccurate program reviews, and overstated capabilities in meeting contract commitments [5]. - As a result of these alleged misrepresentations, the lawsuit claims that investors suffered damages when the true information became public [5].

Core Viewpoint - Global Dividend Growth Split Corp. has announced an extension of the maturity date for its Class A Shares and Preferred Shares from June 30, 2026, to June 27, 2031, allowing shareholders to benefit from an attractive distribution rate and potential capital appreciation [1] Group 1: Shareholder Benefits - Class A shareholders will continue to receive a distribution rate of 10.7% based on the closing price as of August 11, 2025, and can defer potential capital gains tax until shares are disposed of [1] - Over the past five years, Class A Shares have delivered a 19.6% annual return, outperforming the MSCI World High Dividend Yield Total Return Index by 9.9% and the MSCI World Total Return Index by 5.3% [2] - Since inception, Class A shareholders have received cash distributions totaling $8.55 per share, with an option to reinvest these distributions commission-free [2] Group 2: Preferred Shareholder Insights - Preferred shareholders will benefit from preferential cash dividends until June 27, 2031, with a return of 5.1% per annum over the past five years [3] - As of July 31, 2025, Preferred Shares have a high level of downside protection, with 54% asset coverage [3] Group 3: Investment Strategy - The Fund invests in a diversified portfolio of equity securities from large-cap global dividend growth companies, requiring a market capitalization of at least $10 billion and a history or potential for dividend growth [4] - Brompton Funds Limited manages the portfolio, focusing on income and growth investment solutions [5]

Group 1 - Murphy Oil (NYSE: MUR) increased its natural gas production in the second quarter and achieved better realized natural gas prices compared to the previous year [2] - The long-term outlook for natural gas is expected to improve, indicating a potential growth opportunity in the sector [2] - The oil and gas industry is characterized as a boom-bust, cyclical market, requiring patience and experience for successful investment [2]